Evidence map›Paper›PMID 22266115›Full record

ArticleCancer research2012

Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.

Yekaterina Y Zaytseva, Piotr G Rychahou, Pat Gulhati, Victoria A Elliott, William C Mustain, Kathleen O'Connor, Andrew J Morris, Manjula Sunkara, Heidi L Weiss, Eun Y Lee and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Potential Application Value of FASN in the Diagnosis of Colorectal Cancer.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yekaterina Y ZaytsevaMarkey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, USA.
Piotr G Rychahou
Pat Gulhati
Victoria A Elliott
William C Mustain
Kathleen O'Connor
Andrew J Morris
Manjula Sunkara
Heidi L Weiss
Eun Y Lee
B Mark Evers
University of Kentucky · USMarkey Cancer Center · US

Funding

THROMBOSPONDIN1 MEDIATES MACROPHAGE INFILTRATION INTO ADIPOSE TISSUE AND PROMOTEP20RR021954 · NCRR · UNIVERSITY OF KENTUCKY · PI ZHOU, CHANGCHENG · 2008 to 2011
$8.3M
Interdisciplinary Research Training in Cancer BiologyT32CA165990 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, KATHLEEN L. O'CONNOR · 2013 to 2026
$3.2M
Role of Lipid Phosphatases in Cholesterol and Triglyceride SynthesisR01GM050388 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI MORRIS, ANDREW J · 1994 to 2011
$2.7M
Novel Mechanisms of Carcinoma Cell MigrationR01CA109136 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI O'CONNOR, KATHLEEN L. · 2006 to 2016
$2.6M
UK SPORE in Gastrointestinal CancerP20CA150343 · NCI · UNIVERSITY OF KENTUCKY · PI EVERS, BERNARD MARK · 2009 to 2011
$1.5M
Thermo/Finnigan TSQ AM Triple Stage Quadrupole Mass SpectrometerS10RR024598 · NCRR · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2008 to 2008
$493k
Advion Triversa Nanomate/ABSciex Nanospray III Ion Source for Targeted LipidomicsS10RR026884 · NCRR · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2011 to 2011
$106k
NCI NIH HHS P20 CA150343NCI NIH HHS P20CA1530343NCI NIH HHS R01 CA109136NCI NIH HHS T32 CA165990NCRR NIH HHS P20 RR021954NCRR NIH HHS P20RR021954NCRR NIH HHS S10 RR024598NCRR NIH HHS S10 RR026884NIGMS NIH HHS GM50388NIGMS NIH HHS R01 GM050388
6 · The paper itself

Abstract

Fatty acid synthase (FASN) and ATP-citrate lyase, key enzymes of de novo lipogenesis, are significantly upregulated and activated in many cancers and portend poor prognosis. Even though the role of lipogenesis in providing proliferative and survival advantages to cancer cells has been described, the impact of aberrant activation of lipogenic enzymes on cancer progression remains unknown. In this study, we found that elevated expression of FASN is associated with advanced stages of colorectal cancer (CRC) and liver metastasis, suggesting that it may play a role in progression of CRC to metastatic disease. Targeted inhibition of lipogenic enzymes abolished expression of CD44, a transmembrane protein associated with metastases in several cancers including CRC. In addition, inhibition of lipogenic enzymes and reduced expression of CD44 attenuated the activation of MET, Akt, FAK, and paxillin, which are known to regulate adhesion, migration, and invasion. These changes were consistent with an observed decrease in migration and adhesion of CRC cells in functional assays and with reorganization of actin cytoskeleton upon FASN inhibition. Despite the modest effect of FASN inhibition on tumor growth in xenografts, attenuation of lipogenesis completely abolished establishment of hepatic metastasis and formation of secondary metastasis. Together, our findings suggest that targeting de novo lipogenesis may be a potential treatment strategy for advanced CRC.

Indexed as

Signal TransductionAnimalsCell Line, TumorColorectal NeoplasmsDown-RegulationFatty Acid SynthasesFocal Adhesion Kinase 1Gene Knockdown TechniquesHumansHyaluronan ReceptorsLipogenesisLiver NeoplasmsMaleMiceMice, NudeOncogene Protein v-aktCD44 protein, humanFatty Acid SynthasesFocal Adhesion Kinase 1Hyaluronan ReceptorsMET protein, humanOncogene Protein v-aktPaxillinProto-Oncogene Proteins c-metPTK2 protein, humanPXN protein, human

Identifiers

PMID22266115
PMCPMC3596828
OpenAlexW1997243908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.